# US 2001/0034372 A1 · Treatment of fibromyalgia with ubiquinone 10 and succinic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0034372 A1
- Document ID: US20010034372A1
- Status: Published application
- Kind: A1
- Application number: 09/780,299
- Filed: 2001-02-09
- Published: 2001-10-25
- Earliest claimed: 2000-02-09
- Inventors: Paul A. Sneed
- Web page: https://patentgrep.com/patent/US20010034372A1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method is described for using a combination of ubiquinone 10 and succinic acid in the treatment of human patients afflicted with fibromyalgia to alleviate one or more symptoms associated with that disease state. Fibromyalgia positive patients treated buccally, sublingually or by oral ingestion administration of ubiquinone 10 and succinic acid enjoy a reduction in clinical symptoms of the disease.

## Claims

### Claim 1

A method for treating a human patient suffering from fibromyalgia to produce a therapeutic response in said patient, said method comprising the step of administering to the patient ubiquinone 10 and succinic acid each at a dose of about 5 to about 500 mg/70 kg patient.

### Claim 2 (depends on 1)

The method of claim 1 wherein the ubiquinone 10 and the succinic acid are each administered at a dose of about 50 to about 400 mg/70 kg patient.

### Claim 3 (depends on 1)

The method of claim 1 wherein the ubiquinone 10 and the succinic acid are each administered at a dose of about 50 to about 200 mg/70 kg patient.

### Claim 4 (depends on 1)

The method of claim 1 wherein the ubiquinone 10 and the succinic acid are formulated in combination in a pharmaceutically acceptable solid dosage form.

### Claim 5 (depends on 1)

The method of claim 1 wherein the ubiquinone 10 and the succinic acid are formulated in combination in a pharmaceutically acceptable liquid dosage form.

### Claim 6 (depends on 4)

The method of claim 4 wherein the solid dosage form is a saliva-soluble solid dosage form of said combination which is administered by being introduced into the mouth of the patient and held in the mouth for a period of time sufficient to dissolve in saliva in the patient's mouth to form a saliva solution comprising ubiquinone 10 and succinic acid.

### Claim 7 (depends on 6)

The method of claim 6 wherein the solid dosage form is a lozenge.

### Claim 8 (depends on 1)

The method of claim 1 wherein the ubiquinone 10 and the succinic acid are administered by oral ingestion.

### Claim 9 (depends on 1)

The method of claim 1 wherein the ubiquinone 10 and the succinic acid are administered bucally.

### Claim 10 (depends on 1)

The method of claim 1 wherein the ubiquinone 10 and the succinic acid are administered sublingually.

### Claim 11 (depends on 1)

The method of claim 1 wherein the ubiquinone 10 and the succinic acid are administered parenterally.

### Claim 12 (depends on 1)

The method of claim 1 wherein the dose of ubiquinone 10 and succinic acid is administered 1 to 4 times a day until the patient's symptoms of fibromyalgia have subsided.

### Claim 13

A pharmaceutical composition comprising therapeutically effective amounts of ubiquinone 10 and succinic acid as the active ingredients, and a pharmaceutically acceptable carrier therefor.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13 in the form of a liquid solution.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13 in the form of a capsule or caplet.

### Claim 16 (depends on 13)

The pharmaceutical composition of claim 13 in the form of a tablet.

### Claim 17 (depends on 13)

The pharmaceutical composition of claim 13 in gel-seal form.

### Claim 18 (depends on 13)

The pharmaceutical composition of claim 13 in the form of a lozenge.

### Claim 19 (depends on 13)

The pharmaceutical composition of claim 13 adapted for oral administration.

### Claim 20 (depends on 13)

The pharmaceutical composition of claim 13 adapted for parenteral administration.
